Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Infectious DiseasePipeline Analysis

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1793760

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1793760

Q Fever

PUBLISHED:
PAGES: 367 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5850
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Q Fever Market to Reach US$508.1 Million by 2030

The global market for Q Fever estimated at US$425.6 Million in the year 2024, is expected to reach US$508.1 Million by 2030, growing at a CAGR of 3.0% over the analysis period 2024-2030. Acute Q Fever, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$312.1 Million by the end of the analysis period. Growth in the Chronic Q Fever segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$115.9 Million While China is Forecast to Grow at 5.5% CAGR

The Q Fever market in the U.S. is estimated at US$115.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$98.7 Million by the year 2030 trailing a CAGR of 5.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.

Global Q Fever Market - Key Trends & Drivers Summarized

Why Is Q Fever Emerging as a Public Health and Veterinary Surveillance Priority?

Q Fever, caused by the bacterium Coxiella burnetii, is a zoonotic disease that poses significant health risks to both humans and livestock. While often underdiagnosed, Q Fever outbreaks are increasingly documented across rural and peri-urban regions worldwide, where animal-human interface is pronounced. The disease primarily affects individuals in direct contact with farm animals, including veterinarians, abattoir workers, dairy farmers, and herders. In humans, Q Fever can present in acute or chronic forms, leading to febrile illness, pneumonia, or endocarditis in severe cases.

The growing incidence of zoonotic spillover events and intensified livestock production have prompted increased focus on Q Fever surveillance and diagnostics. Climate change, globalization of animal trade, and shifting land-use patterns are contributing to the spread of C. burnetii in previously unaffected geographies. Additionally, the bacterium’s environmental resilience and potential for aerosol transmission underscore its biosecurity relevance. Public health authorities are now prioritizing integrated “One Health” strategies to control Q Fever outbreaks through coordinated veterinary and human health interventions.

Which Diagnostics, Treatment Strategies, and At-Risk Populations Are Defining Market Dynamics?

Diagnosis of Q Fever relies on a combination of serological and molecular tests. Indirect immunofluorescence assay (IFA) remains the gold standard, while ELISA and PCR-based techniques are increasingly employed for both acute and chronic cases. Point-of-care diagnostics are being explored for field deployment in outbreak-prone rural settings. However, the low specificity of early clinical symptoms often leads to delayed diagnosis and inappropriate empirical treatment, increasing the risk of disease progression and complications.

Doxycycline is the standard treatment for acute Q Fever and remains the first-line therapy for high-risk occupational exposure. Chronic Q Fever, especially with cardiac involvement, requires prolonged treatment combining doxycycline with hydroxychloroquine. Vaccination plays a limited but significant role-Australia remains one of the few countries with an approved Q Fever vaccine (Q-Vax), primarily targeting agricultural workers. Efforts are underway to develop next-generation vaccines with broader safety profiles and mass immunization potential, especially in high-incidence regions like the Netherlands, parts of Africa, and Central Asia.

How Are Biosecurity Measures, Disease Monitoring, and Regulatory Responses Influencing Control Strategies?

Enhanced veterinary surveillance and livestock management practices are central to Q Fever control. Measures such as animal quarantine, monitoring of parturition areas, proper disposal of placenta and manure, and control of animal movement are critical in reducing bacterial shedding and aerosol dispersion. In endemic zones, routine serological testing in goats, sheep, and cattle-along with culling or vaccination strategies-is being mandated to limit transmission risks.

Public health responses are evolving to include early-warning systems, outbreak modeling, and mandatory disease notification protocols. The adoption of real-time GIS mapping, environmental sampling, and weather-based risk modeling is helping health authorities anticipate and pre-empt potential outbreaks. Integration of Q Fever monitoring into broader zoonotic disease surveillance frameworks is being supported by international bodies such as WHO, OIE, and FAO under the One Health Initiative. Regulatory alignment between veterinary and medical health systems is a key enabler for rapid containment and response coordination.

What Factors Are Driving the Growth of the Global Q Fever Diagnostics and Therapeutics Market?

The growth in the global Q Fever market is driven by rising disease awareness, improved diagnostic tools, and the increasing frequency of zoonotic disease outbreaks. Occupational exposure in livestock farming, animal transport, and veterinary practice continues to be a major driver of Q Fever incidence. The expansion of commercial livestock farming in developing economies, coupled with inadequate biosecurity practices, is amplifying human-animal pathogen transmission risks and driving demand for disease control solutions.

Heightened bio-preparedness and pandemic surveillance efforts post-COVID-19 are catalyzing government and institutional investments in zoonotic disease research, diagnostic capacity building, and rural health outreach programs. Regional Q Fever outbreaks in Australia, the Netherlands, Kenya, and China have led to increased funding for surveillance and research on vaccine development. Moreover, the integration of Q Fever into multi-pathogen biosurveillance systems is expanding the market for multiplex diagnostics and mobile laboratories.

Leading players in the space include bioMerieux, Thermo Fisher Scientific, QIAGEN, Ceva Sante Animale, and Alere (Abbott). Market growth is expected to accelerate as public health systems institutionalize Q Fever within national zoonotic disease frameworks, prioritize rural diagnostic access, and scale veterinary screening programs. As One Health approaches become central to infectious disease strategy, Q Fever is positioned to remain a critical zoonotic concern demanding sustained diagnostic and therapeutic innovation.

SCOPE OF STUDY:

The report analyzes the Q Fever market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Acute Q Fever, Chronic Q Fever); Medication Type (Antibiotics, Antimalarial, Corticosteroids, Other Medication Types); End-Use (Hospitals End-Use, Clinics End-Use, Research Institutes End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • AtoxBio
  • Basilea Pharmaceutica Ltd
  • Bayer AG
  • BioMerieux SA
  • Ceva Sante Animale
  • CSL Limited
  • Elanco Animal Health
  • Johnson & Johnson Services, Inc.
  • Melinta Therapeutics, Inc.
  • Merck KGaA
  • Merck & Co., Inc.
  • Pfizer Inc.
  • QIAGEN N.V.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries
  • Thermo Fisher Scientific
  • Valneva SE
  • Vaxin Inc.
  • Virbac
  • Yashica Pharmaceuticals Pvt. Ltd

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP37851

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Q Fever - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Zoonotic Diseases Throws the Spotlight on Q Fever Surveillance Programs
    • Expansion of Livestock Farming and Dairy Production Propels Disease Transmission Risks
    • Increasing Demand for Veterinarian-Led Diagnostics Drives Adoption of Q Fever Testing Kits
    • Development of Serological and PCR Assays Enhances Early Detection Capabilities
    • Government Mandates on Animal Vaccination Strengthen Control Program Implementation
    • Growing Public Health Focus on Bioterrorism Risk Accelerates Research on Coxiella burnetii
    • Surge in Tick-Borne and Aerosol-Transmitted Infections Spurs Biosafety Investments
    • Partnerships With Veterinary Institutions Fuel Epidemiological Tracking Initiatives
    • Emerging Molecular Tools and Genotyping Methods Drive Strain Differentiation Efficiency
    • Rising Integration of Q Fever Screening in Livestock Export Protocols Expands Testing Scope
    • Focus on Cross-Reactivity Reduction Improves Diagnostic Accuracy
    • Expansion of One Health Initiatives Strengthens Human-Animal Disease Surveillance Systems
    • Innovation in Point-of-Care Testing Devices Enhances On-Farm Screening Options
    • Increasing Funding for Rickettsial Disease Research Promotes Novel Therapeutic Exploration
    • Regulatory Endorsements for Targeted Antibiotic Therapies Drive Treatment Compliance
    • Development of Cold Chain-Independent Reagents Improves Rural Testing Accessibility
    • Rising Awareness Campaigns Among Livestock Workers Propel Preventive Healthcare Demand
    • Expansion of Agri-Biotech Companies in Developing Regions Supports Commercial Adoption
    • Investment in Portable Lab Equipment Enhances Disease Monitoring in Remote Areas
    • Growth in Travel-Associated Infections and Occupational Exposure Fuels Prophylaxis Demand
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Q Fever Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Q Fever by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Q Fever by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Q Fever by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Acute Q Fever by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Acute Q Fever by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Acute Q Fever by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chronic Q Fever by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Chronic Q Fever by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Chronic Q Fever by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Antimalarial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Antimalarial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Antimalarial by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Medication Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Medication Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Medication Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Q Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • JAPAN
    • Q Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • CHINA
    • Q Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: China 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: China 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: China 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • EUROPE
    • Q Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Q Fever by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Q Fever by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Q Fever by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • FRANCE
    • Q Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: France 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: France 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: France 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • GERMANY
    • Q Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Q Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: Spain 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Russia 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Q Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Q Fever by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Q Fever by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 16-Year Perspective for Q Fever by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Q Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Australia 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • INDIA
    • Q Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: India 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: India 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: India 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: South Korea 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Q Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Q Fever by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Q Fever by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Latin America 16-Year Perspective for Q Fever by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Argentina 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Brazil 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Mexico 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Q Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Q Fever by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Q Fever by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: Middle East 16-Year Perspective for Q Fever by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Iran 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Israel 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: UAE 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • AFRICA
    • Q Fever Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Q Fever by Type - Acute Q Fever and Chronic Q Fever - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Q Fever by Type - Acute Q Fever and Chronic Q Fever Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: Africa 16-Year Perspective for Q Fever by Type - Percentage Breakdown of Value Sales for Acute Q Fever and Chronic Q Fever for the Years 2014, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Q Fever by Medication Type - Antibiotics, Antimalarial, Corticosteroids and Other Medication Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Q Fever by Medication Type - Percentage Breakdown of Value Sales for Antibiotics, Antimalarial, Corticosteroids and Other Medication Types for the Years 2014, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Q Fever by End-Use - Hospitals End-Use, Clinics End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Q Fever by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!